C2T Biosciences

C2T Biosciences is a preclinical-stage biotechnology company developing a proprietary platform for the discovery and development of next-generation targeted therapies. Co-founded by renowned scientists Dr. James Wells (UCSF) and Dr. Peng Wu (Scripps Research), the company leverages its 'Click-to-Target' (C2T) technology to create site-specific bioconjugates and conditional therapeutics. The platform utilizes advanced click chemistry to enable the precise attachment of payloads and the creation of 'masked' proteins that are selectively activated within the tumor microenvironment. This approach is designed to enhance the therapeutic index of antibody-drug conjugates (ADCs) and T-cell engagers by reducing systemic toxicity while maintaining high potency at the disease site. C2T Biosciences is currently advancing a pipeline of oncology-focused programs aimed at addressing unmet needs in solid tumors.